Johnson & Johnson (JNJ) 100.58 $JNJ
Remicade (Ulcerative Colitis) - Forecast and Market Analysis to 2022
M2 - 35 mins ago
Research and Markets (http://www.researchandmarkets.com/research/rhzq3p/remicade) has announced the addition of the "Remicade (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering. During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's (J&J's) Simponi and Takeda's Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively. Remicade (infliximab) is a TNF-a inhibitor that was originally developed by Centocor Ortho Biotech, which is now Janssen Biotech, a subsidiary of J&J. Upon the onset of intestinal inflammation in IBD, a rather aggravated immune response is initiated that is skewed towards a specific T-cell phenotype. This T-cell group (Th1) is attracted to the site of inflammation, where additional white blood cells are recruited. Th1 cells produce large amounts of an inflammatory protein called INF-?, which, in turn, induces the production of the pro-inflammatory cytokine TNF-a in both local and recruited macrophages, as well as in the intestinal epithelial cells Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Remicade (infliximab) 7 Appendix For more information visit http://www.researchandmarkets.com/research/rhzq3p/remicade About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Kappaproct (Ulcerative Colitis) - Forecast and Market Analysis to 2022
M2 - 35 mins ago
Research and Markets (http://www.researchandmarkets.com/research/wrdj75/kappaproct) has announced the addition of the "Kappaproct (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering. During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's (J&J's) Simponi and Takeda's Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively. InDeX Pharmaceuticals is a biopharmaceutical company that focuses on the discovery and development of immunological treatments for diseases with a high unmet need. The company is dedicated to developing personalized treatments and diagnostic assays that will allow physicians to predict which patient populations will respond to specific biologics. InDeX developed Kappaproct with the goal of addressing a significant unmet need in severe UC patients, which is the lack of an effective treatment. Scope - Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Kappaproct including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Kappaproct for the top five countries from 2012 to 2022. - Sales information covered for France, Germany, Italy, Spain and the UK. Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Kappaproct (DIMS 0150) 9 Appendix For more information visit http://www.researchandmarkets.com/research/wrdj75/kappaproct
Global Nutrition and Vitamin Partnering Market: Updated 2014 Report
M2 - 46 mins ago
Research and Markets (http://www.researchandmarkets.com/research/246gjd/nutrition_and) has announced the addition of the "Global Nutrition and Vitamin Partnering Market: Updated 2014 Report" report to their offering. Global Nutrition and Vitamin Partnering Market: Updated 2014 Report is intended to provide the reader with an in-depth understanding and access to nutrition & vitamins trends and structure of deals entered into by leading companies worldwide. This data driven report includes: Trends in nutrition & vitamins dealmaking in the biopharma industry since 2009 Access to summary headline, upfront, milestone and royalty data The leading nutrition & vitamins deals by value since 2009 Global Nutrition and Vitamin Partnering Market: Updated 2014 Report, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type - Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. This data driven report contains over 220 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in nutrition & vitamins partnering Chapter 3 - Leading nutrition & vitamins deals Chapter 4 - Dealmaking directory Chapter 5 - Partnering resource center Appendices Companies Mentioned: - Abbott - Actavis - Actelion - Allergan - Amgen - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Galderma - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Purdue - Roche - Sanofi - Servier - Shionogi - Shire - Takeda - Teva - Valeant - Warner Chilcott - Watson For more information visit http://www.researchandmarkets.com/research/24...rition_and
5 Health-Care Stocks With 36 or More Years of Dividend Increases
Sean Williams, The Motley Fool - Motley Fool - Sun May 18, 9:31AM CDT
According to Susanna Kim of ABC News, between 1910 and 2010, dividend yield and dividend growth represented 90% of stockholders' nominal returns . Dividends really are the "X factor" that can alter your retirement and investing strategy, allowing...
This Diversified Health Care Portfolio Could Yield You 4.2% Annually!
Sean Williams, The Motley Fool - Motley Fool - Sat May 17, 10:32AM CDT
Just two weeks ago I encouraged health-care sector income investors to take a step back and evaluate the quality of dividends they were receiving. While it's not as if big pharma is twiddling its thumbs while paying out hefty dividends, it's...
Medtronic, Inc. Earnings: Will Medical Devices Bounce Back?
Dan Caplinger, The Motley Fool - Motley Fool - Fri May 16, 5:30PM CDT
Next Tuesday, Medtronic will release its quarterly report, and investors have recently sent shares of the medical-device giant to all-time record highs. Even though Medtronic and rivals Johnson & Johnson and Boston Scientific have had to...
Final Glance: Pharmaceuticals companies
AP - Fri May 16, 5:06PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Final Glance: Medical Devices companies
AP - Fri May 16, 5:06PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Midday Glance: Pharmaceuticals companies
AP - Fri May 16, 12:33PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Fri May 16, 12:33PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Next Support Level for Johnson & Johnson (JNJ) is $100.22
Comtex SmarTrend(R) - Fri May 16, 11:45AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) opened today below their pivot of $100.65 and have already reached the first level of support at $100.45. Should the shares continue to fall, the support pivots of $100.22 and $99.79 will be of interest.
Early Glance: Pharmaceuticals companies
AP - Fri May 16, 10:47AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Fri May 16, 10:47AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Global Diabetic Neuropathic Foot Ulcers Therapeutics Clinical Trials Review 2014
M2 - Fri May 16, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mg3g2w/diabetic) has announced the addition of the "Diabetic Neuropathic Foot Ulcers Global Clinical Trials Review, H1, 2014" report to their offering. Diabetic Neuropathic Foot Ulcers Global Clinical Trials Review, H1, 2014" provides data on the Diabetic Neuropathic Foot Ulcers clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic Neuropathic Foot Ulcers. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diabetic Neuropathic Foot Ulcers. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Pfizer Inc. - Olympus Biotech Corporation - HealOr Ltd. (Inactive) - Regenerative Medicine Assets Limited - Johnson & Johnson - Derma Sciences, Inc. - Universidade Estadual Paulista - Department of Health, UK - Kermanshah University of Medical Sciences - The University of Birmingham - University of Miami - Washington University School of Medicine For more information visit http://www.researchandmarkets.com/research/mg3g2w/diabetic
Johnson & Johnson Has Returned 11.3% Since SmarTrend Recommendation (JNJ)
Comtex SmarTrend(R) - Thu May 15, 11:18AM CDT
SmarTrend identified an Uptrend for Johnson & Johnson (NYSE:JNJ) on February 10th, 2014 at $90.44. In approximately 3 months, Johnson & Johnson has returned 11.31% as of today's recent price of $100.67.
Research and Markets: Asia Pacific Facial Care Market 2013-2019 - Industry Analysis, Size, Share, Growth, Trends, and Forecasts
Business Wire - Thu May 15, 9:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ldj749/facial_care) has announced the addition of the "Facial Care Market - Asia-Pacific Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2013 - 2019" report to their offering.
Remicade (Ulcerative Colitis) - Forecast and Market Analysis to 2022
M2 - 35 mins ago
Research and Markets (http://www.researchandmarkets.com/research/rhzq3p/remicade) has announced the addition of the "Remicade (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering. During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's (J&J's) Simponi and Takeda's Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively. Remicade (infliximab) is a TNF-a inhibitor that was originally developed by Centocor Ortho Biotech, which is now Janssen Biotech, a subsidiary of J&J. Upon the onset of intestinal inflammation in IBD, a rather aggravated immune response is initiated that is skewed towards a specific T-cell phenotype. This T-cell group (Th1) is attracted to the site of inflammation, where additional white blood cells are recruited. Th1 cells produce large amounts of an inflammatory protein called INF-?, which, in turn, induces the production of the pro-inflammatory cytokine TNF-a in both local and recruited macrophages, as well as in the intestinal epithelial cells Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Remicade (infliximab) 7 Appendix For more information visit http://www.researchandmarkets.com/research/rhzq3p/remicade About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Kappaproct (Ulcerative Colitis) - Forecast and Market Analysis to 2022
M2 - 35 mins ago
Research and Markets (http://www.researchandmarkets.com/research/wrdj75/kappaproct) has announced the addition of the "Kappaproct (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering. During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's (J&J's) Simponi and Takeda's Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively. InDeX Pharmaceuticals is a biopharmaceutical company that focuses on the discovery and development of immunological treatments for diseases with a high unmet need. The company is dedicated to developing personalized treatments and diagnostic assays that will allow physicians to predict which patient populations will respond to specific biologics. InDeX developed Kappaproct with the goal of addressing a significant unmet need in severe UC patients, which is the lack of an effective treatment. Scope - Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Kappaproct including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Kappaproct for the top five countries from 2012 to 2022. - Sales information covered for France, Germany, Italy, Spain and the UK. Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Kappaproct (DIMS 0150) 9 Appendix For more information visit http://www.researchandmarkets.com/research/wrdj75/kappaproct
Global Nutrition and Vitamin Partnering Market: Updated 2014 Report
M2 - 46 mins ago
Research and Markets (http://www.researchandmarkets.com/research/246gjd/nutrition_and) has announced the addition of the "Global Nutrition and Vitamin Partnering Market: Updated 2014 Report" report to their offering. Global Nutrition and Vitamin Partnering Market: Updated 2014 Report is intended to provide the reader with an in-depth understanding and access to nutrition & vitamins trends and structure of deals entered into by leading companies worldwide. This data driven report includes: Trends in nutrition & vitamins dealmaking in the biopharma industry since 2009 Access to summary headline, upfront, milestone and royalty data The leading nutrition & vitamins deals by value since 2009 Global Nutrition and Vitamin Partnering Market: Updated 2014 Report, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type - Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. This data driven report contains over 220 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in nutrition & vitamins partnering Chapter 3 - Leading nutrition & vitamins deals Chapter 4 - Dealmaking directory Chapter 5 - Partnering resource center Appendices Companies Mentioned: - Abbott - Actavis - Actelion - Allergan - Amgen - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Galderma - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Purdue - Roche - Sanofi - Servier - Shionogi - Shire - Takeda - Teva - Valeant - Warner Chilcott - Watson For more information visit http://www.researchandmarkets.com/research/24...rition_and
5 Health-Care Stocks With 36 or More Years of Dividend Increases
Sean Williams, The Motley Fool - Motley Fool - Sun May 18, 9:31AM CDT
According to Susanna Kim of ABC News, between 1910 and 2010, dividend yield and dividend growth represented 90% of stockholders' nominal returns . Dividends really are the "X factor" that can alter your retirement and investing strategy, allowing...
This Diversified Health Care Portfolio Could Yield You 4.2% Annually!
Sean Williams, The Motley Fool - Motley Fool - Sat May 17, 10:32AM CDT
Just two weeks ago I encouraged health-care sector income investors to take a step back and evaluate the quality of dividends they were receiving. While it's not as if big pharma is twiddling its thumbs while paying out hefty dividends, it's...
Medtronic, Inc. Earnings: Will Medical Devices Bounce Back?
Dan Caplinger, The Motley Fool - Motley Fool - Fri May 16, 5:30PM CDT
Next Tuesday, Medtronic will release its quarterly report, and investors have recently sent shares of the medical-device giant to all-time record highs. Even though Medtronic and rivals Johnson & Johnson and Boston Scientific have had to...
Final Glance: Pharmaceuticals companies
AP - Fri May 16, 5:06PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Final Glance: Medical Devices companies
AP - Fri May 16, 5:06PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Midday Glance: Pharmaceuticals companies
AP - Fri May 16, 12:33PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Fri May 16, 12:33PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Next Support Level for Johnson & Johnson (JNJ) is $100.22
Comtex SmarTrend(R) - Fri May 16, 11:45AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) opened today below their pivot of $100.65 and have already reached the first level of support at $100.45. Should the shares continue to fall, the support pivots of $100.22 and $99.79 will be of interest.
Early Glance: Pharmaceuticals companies
AP - Fri May 16, 10:47AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Fri May 16, 10:47AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Global Diabetic Neuropathic Foot Ulcers Therapeutics Clinical Trials Review 2014
M2 - Fri May 16, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mg3g2w/diabetic) has announced the addition of the "Diabetic Neuropathic Foot Ulcers Global Clinical Trials Review, H1, 2014" report to their offering. Diabetic Neuropathic Foot Ulcers Global Clinical Trials Review, H1, 2014" provides data on the Diabetic Neuropathic Foot Ulcers clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic Neuropathic Foot Ulcers. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diabetic Neuropathic Foot Ulcers. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Pfizer Inc. - Olympus Biotech Corporation - HealOr Ltd. (Inactive) - Regenerative Medicine Assets Limited - Johnson & Johnson - Derma Sciences, Inc. - Universidade Estadual Paulista - Department of Health, UK - Kermanshah University of Medical Sciences - The University of Birmingham - University of Miami - Washington University School of Medicine For more information visit http://www.researchandmarkets.com/research/mg3g2w/diabetic
Johnson & Johnson Has Returned 11.3% Since SmarTrend Recommendation (JNJ)
Comtex SmarTrend(R) - Thu May 15, 11:18AM CDT
SmarTrend identified an Uptrend for Johnson & Johnson (NYSE:JNJ) on February 10th, 2014 at $90.44. In approximately 3 months, Johnson & Johnson has returned 11.31% as of today's recent price of $100.67.
Research and Markets: Asia Pacific Facial Care Market 2013-2019 - Industry Analysis, Size, Share, Growth, Trends, and Forecasts
Business Wire - Thu May 15, 9:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ldj749/facial_care) has announced the addition of the "Facial Care Market - Asia-Pacific Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2013 - 2019" report to their offering.
